3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Oculis Holding AG

Oculis (OCS) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Oculis Holding AG

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

Pipeline and near-term milestones

  • Two late-stage assets: privosegtor across neuroprotection indications and licaminlimab, a genotype-based precision medicine program in dry eye disease.

  • PREDICT-1 top-line results expected within weeks; an IND for the neuro indication was submitted and confirmation was expected in the coming days to weeks.

  • R&D Day planned for December 8, with a PIONEER-1 execution update, refined PREDICT-1 timing and a broader privosegtor indication-development plan.

Licaminlimab

  • TNF-inhibitor antibody fragment designed for high concentration and ocular tissue penetration; TNFR1 biomarker aims to identify patients who are more responsive to TNF inhibition.

  • Across three Phase II trials, the latest symptom study showed exploratory improvement among TNFR1 patients; the latest sign trial showed a prespecified secondary-endpoint effect ~5x all-comers and ~6x the best competing Phase III result.

  • PREDICT-1 randomized 176 patients, two-thirds TNFR1-positive; enrollment exceeded the 160-patient plan as screened patients already in process were allowed to continue.

  • Placebo response is managed with a two-week artificial-tears run-in, exclusion of tear responders, a discomfort-score threshold above 60/100 and TNFR1 enrichment.

  • Management views a good result as doubling the prior 4.3-point drug-placebo difference in TNFR1 patients; responder rate above 25% versus 18% previously in all-comers would be a meaningful benchmark.

Privosegtor

  • Optic neuritis is the initial orphan indication; management cited no existing treatment and highlighted its value as a neuroprotection model using visual function, OCT structure and biomarkers.

  • ACUITY Phase II showed an 18-letter LCVA difference maintained through month six, alongside retinal structural preservation and lower neurofilament and GFAP signals; results supported FDA Breakthrough and EMA PRIME designations.

  • PIONEER-1 is tracking to plan; the goal is 30 of 60 sites activated by year-end, ahead of the December-to-May seasonal period for relapses and optic neuritis.

  • PIONEER-1 uses LCVA as its endpoint, with LCVA 2.5%, GCIPL and neurofilament as secondary measures and GFAP exploratory.

  • FDA alignment calls for two studies to provide 300 exposed patients; PIONEER-1/2 support optic neuritis, while PIONEER-2/3 support acute MS relapse, including ambulatory relapse in PIONEER-3.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Oculis